Premium
Maze Therapeutics Inc (MAZE)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | Mr. Atul DandekarChief Strategy & Business Officer | -7,50k | 119,40k | Derivative Exercise and Sale | 10,42 - 26,34 | 24,81k | - |
| 2026-05-22 | Dr. Jason V. ColomaCEO & Director | -32,56k | 847,05k | Automatic Disposition | 26,00 - 26,02 | 379,51k | -7,90% |
| 2026-05-15 | Dr. Jason V. ColomaCEO & Director | -1,94k | 50,39k | Automatic Disposition | 26,00 | 412,07k | -0,47% |
| 2026-05-14 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -15,00k | 237,05k | Derivative Exercise and Sale | 10,42 - 26,22 | - | - |
| 2026-05-04 | Mr. Atul DandekarChief Strategy & Business Officer | 14,31k | 149,06k | Derivative Exercise and Retained Stock | 10,42 | 24,81k | 136,20% |
| 2026-05-04 | Dr. Charles J. HomcyDirector | -7,42k | 0,00 | Other Disposition | - | 31,11k | -19,26% |
| 2026-04-29 | Mr. Atul DandekarChief Strategy & Business Officer | -7,50k | 112,15k | Derivative Exercise and Sale | 10,42 - 25,37 | 10,50k | - |
| 2026-04-01 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -15,00k | 285,60k | Derivative Exercise and Sale | 10,42 - 31,07 | 0,00 | - |
| 2026-04-01 | Ms. Amy BachrodtInitié | -2,50k | 47,56k | Derivative Exercise and Sale | 10,42 - 30,34 | 12,97k | - |
| 2026-03-30 | Mr. Atul DandekarChief Strategy & Business Officer | -7,50k | 141,87k | Derivative Exercise and Sale | 10,42 - 30,02 | 10,50k | - |
| 2026-03-20 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -15,00k | 580,14k | Derivative Exercise and Sale | 10,42 - 50,02 | 0,00 | - |
| 2026-03-10 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -30,00k | 1,20M | Derivative Exercise and Sale | 10,42 - 51,02 | 0,00 | - |
| 2026-02-27 | Mr. Atul DandekarChief Strategy & Business Officer | -7,50k | 262,57k | Derivative Exercise and Sale | 10,42 - 45,72 | 10,50k | - |
| 2026-03-02 | Ms. Amy BachrodtInitié | -5,00k | 173,91k | Derivative Exercise and Sale | 10,42 - 45,47 | 12,97k | - |
| 2026-02-02 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -15,00k | 534,03k | Derivative Exercise and Sale | 10,42 - 47,23 | - | - |
| 2026-02-02 | Ms. Amy BachrodtInitié | -5,00k | 178,12k | Derivative Exercise and Sale | 10,42 - 46,63 | 12,97k | - |
| 2026-01-29 | Mr. Atul DandekarChief Strategy & Business Officer | -7,50k | 253,84k | Derivative Exercise and Sale | 10,42 - 45,01 | 10,50k | - |
| 2026-01-22 | Ms. Amy BachrodtInitié | -5,00k | 175,51k | Derivative Exercise and Sale | 10,42 - 45,52 | 12,97k | - |
| 2026-01-07 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -25,16k | 749,17k | Derivative Exercise and Sale | 10,42 - 40,20 | 0,00 | - |
| 2026-01-06 | Dr. Catherine Angell SohnIndependent Non-Employee Director | -29,41k | 842,57k | Derivative Exercise and Sale | 10,42 - 39,11 | 0,00 | - |
| 2026-01-02 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -4,84k | 145,19k | Derivative Exercise and Sale | 10,42 - 40,43 | 0,00 | - |
| 2026-01-02 | Ms. Amy BachrodtInitié | -5,00k | 143,65k | Derivative Exercise and Sale | 10,42 - 39,57 | 12,97k | - |
| 2025-12-29 | Mr. Atul DandekarChief Strategy & Business Officer | -72,50k | 2,19M | Derivative Exercise and Sale | 10,42 - 41,13 | 10,50k | - |
| 2025-12-29 | Dr. Harold S. BernsteinPresident of Research & Development and Chief Medical Officer | -45,00k | 1,36M | Derivative Exercise and Sale | 10,42 - 40,93 | - | - |
| 2025-12-29 | Ms. Amy BachrodtInitié | -15,00k | 449,87k | Derivative Exercise and Sale | 10,42 - 41,16 | 12,97k | - |
| 2025-11-04 | Third Rock Ventures, LLCSociété | -1,60M | 0,00 | Other Disposition | - | 5,42M | -22,78% |
| 2025-10-23 | Dr. Charles J. HomcyDirector | -28,42k | 0,00 | Other Disposition | - | 37,05k | -43,41% |
| 2025-09-15 | Dr. Richard H. SchellerIndependent Non-Employee Director | -20,74k | 464,03k | Vente | 22,37 | 0,00 | -100,00% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
